JP7406263B2 - 改変アデノウイルス及びこれを含む医薬 - Google Patents
改変アデノウイルス及びこれを含む医薬 Download PDFInfo
- Publication number
- JP7406263B2 JP7406263B2 JP2021507412A JP2021507412A JP7406263B2 JP 7406263 B2 JP7406263 B2 JP 7406263B2 JP 2021507412 A JP2021507412 A JP 2021507412A JP 2021507412 A JP2021507412 A JP 2021507412A JP 7406263 B2 JP7406263 B2 JP 7406263B2
- Authority
- JP
- Japan
- Prior art keywords
- gene
- adenovirus
- cells
- enhancer
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims description 113
- 239000003814 drug Substances 0.000 title claims description 28
- 229940079593 drug Drugs 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 131
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 39
- 239000003623 enhancer Substances 0.000 claims description 34
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 31
- 230000014509 gene expression Effects 0.000 claims description 29
- 108020004999 messenger RNA Proteins 0.000 claims description 26
- 230000001965 increasing effect Effects 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 12
- 108020005176 AU Rich Elements Proteins 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 230000006641 stabilisation Effects 0.000 claims description 8
- 238000011105 stabilization Methods 0.000 claims description 8
- 108091026890 Coding region Proteins 0.000 claims description 5
- 238000013518 transcription Methods 0.000 claims description 5
- 230000035897 transcription Effects 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 description 81
- 241000700605 Viruses Species 0.000 description 26
- 108700005077 Viral Genes Proteins 0.000 description 21
- 206010028980 Neoplasm Diseases 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 230000000694 effects Effects 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 101150075174 E1B gene Proteins 0.000 description 13
- 230000022534 cell killing Effects 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 7
- 108010065850 Tristetraprolin Proteins 0.000 description 6
- 102100031622 mRNA decay activator protein ZFP36 Human genes 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000055765 ELAV-Like Protein 1 Human genes 0.000 description 5
- 108700015856 ELAV-Like Protein 1 Proteins 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 230000000445 cytocidal effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 108700025906 fos Genes Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 244000309459 oncolytic virus Species 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 101710199711 Early E1A protein Proteins 0.000 description 4
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108700026226 TATA Box Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002437 synoviocyte Anatomy 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 101150005585 E3 gene Proteins 0.000 description 2
- 102100036123 Far upstream element-binding protein 2 Human genes 0.000 description 2
- 101710133942 Far upstream element-binding protein 2 Proteins 0.000 description 2
- 108091021225 Heterogeneous Nuclear Ribonucleoprotein D0 Proteins 0.000 description 2
- 102000036541 Heterogeneous Nuclear Ribonucleoprotein D0 Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001135569 Human adenovirus 5 Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000013601 cosmid vector Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000007651 self-proliferation Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229940123373 Adenovirus E1A gene Drugs 0.000 description 1
- 101100004408 Arabidopsis thaliana BIG gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101100485279 Drosophila melanogaster emb gene Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102100029095 Exportin-1 Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 101150094313 XPO1 gene Proteins 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108700002148 exportin 1 Proteins 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108700024542 myc Genes Proteins 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019053895 | 2019-03-20 | ||
| JP2019053895 | 2019-03-20 | ||
| PCT/JP2020/012196 WO2020189749A1 (ja) | 2019-03-20 | 2020-03-19 | 改変アデノウイルス及びこれを含む医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020189749A1 JPWO2020189749A1 (zh) | 2020-09-24 |
| JPWO2020189749A5 JPWO2020189749A5 (zh) | 2022-03-10 |
| JP7406263B2 true JP7406263B2 (ja) | 2023-12-27 |
Family
ID=72520204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507412A Active JP7406263B2 (ja) | 2019-03-20 | 2020-03-19 | 改変アデノウイルス及びこれを含む医薬 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220152133A1 (zh) |
| EP (1) | EP3943113A4 (zh) |
| JP (1) | JP7406263B2 (zh) |
| CN (1) | CN113573741A (zh) |
| CA (1) | CA3135295A1 (zh) |
| TW (1) | TWI819203B (zh) |
| WO (1) | WO2020189749A1 (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002525063A (ja) | 1998-09-10 | 2002-08-13 | キャリドン，インコーポレイティド | 細胞状態特異的反応エレメントを含むアデノウイルスベクター及びその使用方法 |
| JP2016160249A (ja) | 2015-03-05 | 2016-09-05 | 国立大学法人北海道大学 | 腫瘍溶解改変アデノウイルス、疾患治療用改変ウイルス及びこれらを含むウイルス製剤 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9017672B2 (en) * | 2012-05-11 | 2015-04-28 | Immunicum Aktiebolag | Hexon Tat-PTD modified adenovirus and uses thereof |
-
2020
- 2020-03-19 CN CN202080021634.9A patent/CN113573741A/zh active Pending
- 2020-03-19 EP EP20774238.8A patent/EP3943113A4/en active Pending
- 2020-03-19 TW TW109109287A patent/TWI819203B/zh active
- 2020-03-19 CA CA3135295A patent/CA3135295A1/en active Pending
- 2020-03-19 JP JP2021507412A patent/JP7406263B2/ja active Active
- 2020-03-19 US US17/439,184 patent/US20220152133A1/en active Pending
- 2020-03-19 WO PCT/JP2020/012196 patent/WO2020189749A1/ja active Search and Examination
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002525063A (ja) | 1998-09-10 | 2002-08-13 | キャリドン，インコーポレイティド | 細胞状態特異的反応エレメントを含むアデノウイルスベクター及びその使用方法 |
| JP2016160249A (ja) | 2015-03-05 | 2016-09-05 | 国立大学法人北海道大学 | 腫瘍溶解改変アデノウイルス、疾患治療用改変ウイルス及びこれらを含むウイルス製剤 |
Non-Patent Citations (4)
| Title |
|---|
| ELOIT M. et al.，Isogenic adenoviruses type 5 expressing or not expressing the E1A gene: efficiency as virus vectors in the vaccination of permissive and non-permissive species，Journal of General Virology，1995年，vol.76，p.1583-1589 |
| HALBERT D. N. et al.，Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff，Journal of Virology，1985年，vol.56, no.1，p.250-257 |
| HEARING P. et al.，The adenovirus type 5 E1A enhancer contains two functionally distinct domains: one is specific for E1A and the other modulates all early units in Cis，Cell，1986年，vol.45，p.229-236 |
| MIKAWA Y. et al.，Conditionally replicative adenovirus controlled by the stabilization system of AU-rich elements containing mRNA，Cancers，2020年05月11日，vol.12，e.1205 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220152133A1 (en) | 2022-05-19 |
| TW202102677A (zh) | 2021-01-16 |
| WO2020189749A1 (ja) | 2020-09-24 |
| TWI819203B (zh) | 2023-10-21 |
| EP3943113A1 (en) | 2022-01-26 |
| JPWO2020189749A1 (zh) | 2020-09-24 |
| CN113573741A (zh) | 2021-10-29 |
| EP3943113A4 (en) | 2023-05-10 |
| CA3135295A1 (en) | 2020-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6817979B2 (ja) | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 | |
| JP6639412B2 (ja) | アルブミン結合部分を含んでなるアデノウイルス | |
| JP3875990B2 (ja) | 組換えアデノウイルスベクターおよび使用方法 | |
| FI118011B (fi) | Menetelmä replikaatiokyvyn suhteen puutteellisen yhdistelmä-DNA-adenoviruksen tuottamiseksi | |
| Yaghchi et al. | Vaccinia virus, a promising new therapeutic agent for pancreatic cancer | |
| Zhu et al. | Oncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo | |
| JPH06508039A (ja) | 抗腫瘍治療のためのサイトカインを発現する組換え型欠損アデノウイルス | |
| Lei et al. | An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors | |
| KR100368292B1 (ko) | 암의유전자치료용재조합아테노바이러스 | |
| EP1545627A2 (en) | Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors | |
| EP1196616A2 (en) | Replication-competent anti-cancer vectors | |
| JP3867968B2 (ja) | 腫瘍細胞において選択的に増殖する腫瘍融解ウイルス | |
| Liu et al. | Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a trend in both cancer gene therapy and cancer virotherapy | |
| JP7406263B2 (ja) | 改変アデノウイルス及びこれを含む医薬 | |
| JP2016160249A (ja) | 腫瘍溶解改変アデノウイルス、疾患治療用改変ウイルス及びこれらを含むウイルス製剤 | |
| JP4431091B2 (ja) | 組換えアデノウイルスベクターおよび使用方法 | |
| US11951141B2 (en) | Replication-enhanced oncolytic adenoviruses | |
| US20050271622A1 (en) | Construct of tumor-selective recombinant adenovirus, method for preparing the same and use thereof | |
| WO2021020554A1 (ja) | ＲＥＩＣ／Ｄｋｋ－３遺伝子と抗腫瘍剤との併用による肝臓がんの治療方法 | |
| WO2022170919A1 (zh) | 一种重组溶瘤腺病毒及其应用 | |
| Edelstein et al. | 981. Gene Therapy Clinical Trials Worldwide 1989-2003: An Overview | |
| Taylor et al. | Viral Oncolysis or Virotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A5211 Effective date: 20210824 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230131 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231205 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231208 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7406263 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |